Geographic Atrophy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Geographic Atrophy - Pipeline Review, H2 2018’, provides an overview of the Geographic Atrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Geographic Atrophy

- The report reviews pipeline therapeutics for Geographic Atrophy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Geographic Atrophy therapeutics and enlists all their major and minor projects

- The report assesses Geographic Atrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Geographic Atrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Geographic Atrophy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Geographic Atrophy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achillion Pharmaceuticals Inc

Acucela Inc

Alkeus Pharmaceuticals Inc

Allergan Plc

Apellis Pharmaceuticals Inc

Cell Cure Neurosciences Ltd

Colby Pharmaceutical Co

F. Hoffmann-La Roche Ltd

Foamix ...

Achillion Pharmaceuticals Inc

Acucela Inc

Alkeus Pharmaceuticals Inc

Allergan Plc

Apellis Pharmaceuticals Inc

Cell Cure Neurosciences Ltd

Colby Pharmaceutical Co

F. Hoffmann-La Roche Ltd

Foamix Pharmaceuticals Ltd

Genentech Inc

GenSight Biologics SA

Ionis Pharmaceuticals Inc

Johnson & Johnson

Novartis AG

NovelMed Therapeutics Inc

Ophthotech Corp

Ra Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Geographic Atrophy – Overview

Geographic Atrophy – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Geographic Atrophy – Overview

Geographic Atrophy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Geographic Atrophy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Geographic Atrophy – Companies Involved in Therapeutics Development

Achillion Pharmaceuticals Inc

Acucela Inc

Alkeus Pharmaceuticals Inc

Allergan Plc

Apellis Pharmaceuticals Inc

Cell Cure Neurosciences Ltd

Colby Pharmaceutical Co

F. Hoffmann-La Roche Ltd

Foamix Pharmaceuticals Ltd

Genentech Inc

GenSight Biologics SA

Ionis Pharmaceuticals Inc

Johnson & Johnson

Novartis AG

NovelMed Therapeutics Inc

Ophthotech Corp

Ra Pharmaceuticals Inc

Geographic Atrophy – Drug Profiles

ACH-5548 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACU-6151 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALK-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacincaptad pegol sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimonidine tartrate implant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLG-561 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPC-551 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-30 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-030 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMR-59 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FB-LRx – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPE-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-5072 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OpRegen – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palucorcel – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6147 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7171009 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Inhibit Complement Factor D for Dry (atrophic) Macular Degeneration – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Inhibit Complement Factor D for Geographic Atrophy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 3 to Inhibit Complement Factor D for Geographic Atrophy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit Factor D for Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesidolumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Geographic Atrophy – Dormant Projects

Geographic Atrophy – Discontinued Products

Geographic Atrophy – Product Development Milestones

Featured News & Press Releases

Jul 24, 2018: Apellis Pharmaceuticals APL-2 receives fast track designation from FDA for the treatment of patients with geographic atrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Geographic Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Geographic Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Geographic Atrophy – Pipeline by Achillion Pharmaceuticals Inc, H2 2018

Geographic Atrophy – Pipeline by Acucela Inc, H2 2018

Geographic Atrophy – Pipeline by Alkeus Pharmaceuticals Inc, H2 2018

Geographic Atrophy – Pipeline by Allergan Plc, H2 2018

Geographic Atrophy – Pipeline by Apellis Pharmaceuticals Inc, H2 2018

Geographic Atrophy – Pipeline by Cell Cure Neurosciences Ltd, H2 2018

Geographic Atrophy – Pipeline by Colby Pharmaceutical Co, H2 2018

Geographic Atrophy – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Geographic Atrophy – Pipeline by Foamix Pharmaceuticals Ltd, H2 2018

Geographic Atrophy – Pipeline by Genentech Inc, H2 2018

Geographic Atrophy – Pipeline by GenSight Biologics SA, H2 2018

Geographic Atrophy – Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Geographic Atrophy – Pipeline by Johnson & Johnson, H2 2018

Geographic Atrophy – Pipeline by Novartis AG, H2 2018

Geographic Atrophy – Pipeline by NovelMed Therapeutics Inc, H2 2018

Geographic Atrophy – Pipeline by Ophthotech Corp, H2 2018

Geographic Atrophy – Pipeline by Ra Pharmaceuticals Inc, H2 2018

Geographic Atrophy – Dormant Projects, H2 2018

Geographic Atrophy – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Geographic Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Geographic Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports